drugset / Trial / NCT05822544
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
RandomizedSequentialDouble-blindTreatment
Summary
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects. The phase 1b portion of the study is designed to assess the safety, tolerability, and PK of TLC-6740 in subjects with obesity, with or without type 2 diabetes mellitus.
Timeline
- Start
- 2023-04-22
- Primary completion
- 2026-02
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | — | Oral |
| Subject | Omeprazole | Other / unclassified | — | Oral |
| Subject | Rifampicin | Small molecule | — | Oral |
| Subject | TLC-6740 | Unknown | — | Oral |
| Subject | Voriconazole | Small molecule | — | Oral |
| Background | Tirzepatide | Peptide | — | Subcutaneous |